Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial
Yair Lotan(Southwestern Medical Center), Stephen A. Boorjian(Mayo Clinic), Wassim Kassouf(McGill University), Susan Jewell(Netherlands Institute for Radio Astronomy), Ajith M. Joseph(Abbott (United States)), Siamak Daneshmand(Unknown), Brant A. Inman(Duke Medical Center), Edward M. Messing(University of Rochester Medical Center), Leah Davis(Duke Medical Center), H. Tony Marble(Abbott (United States)), Daniel Canter(Ochsner Medical Center)
Cited by 27
Related Papers
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603
Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)
|World Journal of Urology|2016|471
Fluorescence In Situ Hybridization (FISH) as an Ancillary Diagnostic Tool in the Diagnosis of Melanoma
|The American Journal of Surgical Pathology|2009|470
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2021|411
Spectrum of diverse genomic alterations define non–clear cell renal carcinoma subtypes
|Nature Genetics|2014|359